Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
The world's largest contract research organization, Quintiles Transnational, has been operating in Asia-Pacific region for more than 17 years. Two Quintiles Asia executives, Quintiles India CEO Dr. Ferzaan Engineer and Senior VP and Head of Clinical Development for Quintiles Asia-Pacific Dr. Anand Tharmaratnam, recently shared their views with PharmAsia News on the changing CRO market in the region.
You may also be interested in...
India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?
MUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business
India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?
MUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business
Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News (Part 2 of 2)
The world's largest contract research organization, Quintiles Transnational has been operating in Asia-Pacific for more than 17 years. Two Asia-based executives, Quintiles India CEO Dr. Ferzaan Engineer and Senior VP and Head of Clinical Development for Quintiles Asia-Pacific Dr. Mr. Tharmaratnam recently shared their views with PharmAsia News on the changing CRO landscape in Asia. In part one of the interview, they talked about clinical research and development trends in the region, and opportunities and challenges for multinational CROs operating in China.